Home About Us LungVantage Active Targeting Research Leadership News Contact Viomics - Early Detection of Cancer


January 5, 2016 – Viomics presents a poster at the AACR-IASLC annual meeting titled Whole blood FPR1 mRNA expression identifies both non-small cell and small cell lung cancer. Read the abstract here.

June 11, 2013 – Viomics is awarded $250,000 as a winner of the Arizona Innovation Challenge, one of the top grant funds available for cutting edge start up organizations in the country. See additional details at here.

December 13, 2012 – Viomics launches clinicals trials for LungVantage with IRB-approved prospective collection of healthy volunteers and pre-surgical lung cancer patient plasma at multiple hospitals across the United States.

September 9, 2012 – The Viomics executive team are authors of groundbreaking Nature manuscript in the top-tier journal Nature titled: “Comprehensive genomic characterization of squamous cell lung cancers” as part of The Cancer Genome Atlas Research Network.  See full text of the article at: http://www.nature.com/nature/journal/v489/n7417/full/nature11404.html

July 1, 2012 – Viomics leverages core controls and RNA detection technology to validate ActiveTargeting™ assays to screen and precisely quantify plasma ALK mRNA concentration.

May 25, 2012- Viomics selected as a winner of the Edson Entrepreneur Initiative from a field of 340 competitors. Read more at ASU News.

May 3, 2012- Preliminary results from Viomics' LungVantage assay was presented by Qiagen marketing manager Anita Suresh during the Qiagen Symposium in San Diego, CA to demonstrate feasibility of nucleic acid diagnostics. Viomics CSO Scott Morris also presented novel technologies for assessing quality of formalin fixed, paraffin-embedded (FFPE) tissues, drawing major interest from potential commercial partners.


©Copyright 2012 Viomics Inc. All rights reserved.